DRI Healthcare Trust Comments on Extension of Review Period for pacritinib
30 November 2021 - 11:40PM
PR Newswire (Canada)
TORONTO, Nov. 30, 2021 /CNW/ - DRI Healthcare Trust (TSX:
DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced that it
has been notified by CTI BioPharma Corp. (CTI) that the U.S. Food
and Drug Administration (FDA) has extended the review period for
the New Drug Application for pacritinib for the treatment of adult
Myelofibrosis patients with severe thrombocytopenia. According to
CTI, the PDUFA date has been extended by three months to
February 28, 2022. Approval of
pacritinib by the FDA is a condition to the acquisition by DRI of a
tiered royalty on pacritinib, as announced on August 25, 2021.
About DRI Healthcare Trust
DRI Healthcare Trust provides unitholders with differentiated
exposure to the anticipated growth in the global pharmaceuticals
and biotechnology markets. Our business model is focused on
managing and growing a diversified portfolio of pharmaceutical
royalties with the aim to deliver attractive growth in cash royalty
receipts over the long term. DRI Healthcare Trust is an
unincorporated open-ended trust governed by the laws of the
Province of Ontario, externally
managed by its manager, DRI Capital Inc. DRI Healthcare Trust's
units are listed and trade on the Toronto Stock Exchange in
Canadian dollars under the symbol "DHT.UN" and in U.S. dollars
under the symbol "DHT.U".
SOURCE DRI Healthcare Trust
Copyright 2021 Canada NewsWire
DRI Healthcare (TSX:DHT.U)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
DRI Healthcare (TSX:DHT.U)
Historical Stock Chart
Von Apr 2023 bis Apr 2024